Clinical trial
The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features
NCT00035321 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- The Study of Olanzapine Plus Fluoxetine in Combination for Treatment-Resistant Depression Without Psychotic Features
- Lead sponsor
- Eli Lilly and Company
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- April 30, 2002
- Completion date
- July 31, 2005
- Enrollment
- 600
- Sites
- 33
Conditions
As the registry lists them; a condition with its own page is linked.